Thalia Therapeutics Plc (THAT.L)
LSE · GBp · Healthcare · Biotechnology
£0.60 (+4.35%) as of
Key statistics
- Market cap
- 10.65M
- EPS (TTM)
- -0.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.4000 – 0.9500
- Beta
- 0.71
- Revenue (TTM)
- 7.22k
- Profit margin
- 0.00%
- Volume
- 10.36k
About Thalia Therapeutics Plc
Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. The company develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines. It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. The company has collaboration with the Centre for Continuous Manufacturing and Advanced Crystallisation at the University of Strathclyde to support the scale-up and characterisation of Nuvec. The company was formerly known as N4 Pharma Plc and changed its name to Thalia Therapeutics Plc in March 2026. Thalia Therapeutics Plc was incorporated in 1979 and is based in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- London, United Kingdom
- Employees
- 3
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.